The 12 months volume of global pharmaceutical market
By January 2012 the total sales volume in the global pharmaceutical market for one year amounted to 554.8 billion USA dollars (in terms of MAT – Moving annual total).
The maximum contribution to the total global pharmaceutical market is traditionally provided by the United States. And the most high growth in sales was showed by pharmaceutical markets in Latin America countries such as Venezuela, Argentina and Brazil. Active development is also indicated at the Chinese pharmaceutical market.
In the pharmacotherapeutic structure of the global pharmaceutical market the leader among the groups of ATC classification of the third level by January 2012 had steadily been medicines of the group C10A “Hypolipidemic products, monocomponent”. At the 2nd place there is a group of A02B “Medical preparations for treatment of peptic ulcer and gastroesophageal reflux disease”; on the 3rd - N05A “Antipsychotic medicinal products”.
On the global pharmaceutical market by January 2012 the leader in sales in monetary terms was traditionally Lipitor ® (atorvastatin). The 2, 3 and 4th lines were taken by Plavix ® (clopidogrel), Crestor ® (rosuvastatin) and Seretide ® (fluticasone + salmeterol). At the 5th position there is Nexium ® (esomeprazole).
Top 5 corporates on sales volume in monetary terms at the global pharmaceutical market is stable with respect to previous periods. For 12 months - by January 2012 - it was led by the company “Pfizer”; the 2nd place was taken by the company “Novartis”, the 3rd, 4th and 5th place – by “AstraZeneca”, “Merck & Co.” and “GlaxoSmithKline”, respectively.